Prescription of targeted therapies in combination with chemotherapy for stage III colon cancer does not show benefits, and the importance of RAS and BRAF V600E mutations in prognosis is established. Starting adjuvant chemotherapy more than 8 weeks after tumor resection increases the risk of death. Complications post-surgery and overall health can also impact prognosis.